Laguna ONhE
Laguna ONhE is a deep learning algorithm that analyzes a color fundus photograph to estimate optic nerve hemoglobin and cupping in seconds, helping clinicians screen for glaucoma. Spanish developer INSOFT distributes it through the RetinaLyze telemedicine platform.
What is Laguna ONhE?
Laguna ONhE is a colorimetric image analysis algorithm for eye fundus photographs, developed by Instrumentación y Oftalmología INSOFT SL, a Spanish ophthalmology R&D company based in Santa Cruz de Tenerife. From a single color photograph of the eye fundus, it estimates topographically the relative concentrations of hemoglobin in the optic nerve and assesses cupping of the optic disc. The declared purpose is the diagnosis and screening of glaucoma.
The method rests on deep learning trained on large quantities of images, which is what lets it return a result in only a few seconds and fully automatically. It works over the internet: the developer states that it analyzes in seconds the fundus images it receives from anywhere in the world. The site names three national patents, US20140340636A1 in the United States, DE112012004879T5 in Germany and JP5960835B2 in Japan, and states that the method carries a CE mark, though no certificate number, notified body or device class is published.
One point matters for anyone evaluating it: Laguna ONhE is not sold by INSOFT. The site states that it is being commercialized on the telemedicine platform of the Danish company Retinalyze System A/S, where it appears as RetinaLyze Glaucoma. INSOFT's own business model is royalties per instrument or program sold, paid by the companies it has worked for.
INSOFT was founded in 1990 by Prof. Manuel González de la Rosa, a professor of ophthalmology. Earlier methods from the same team became standards in visual field testing: TOP, distributed by Interzeag and then Haag-Streit, Pulsar on the Octopus 600, and Spark, TNT and PATH with OCULUS Optikgeräte GmbH. The site claims thousands of Octopus instruments distributed worldwide and millions of examinations performed.
Development continues. Project IDI-20240516, running from 1 May 2024 to 30 April 2026 and co-financed by ERDF 2021-2027 and CDTI, aims to analyze the three-dimensional morphology of nerve tissue from two-dimensional images and to associate perfusion information with functional perimetry data. An earlier project, C007/20-ED, refined, extended and validated the algorithm with Big Data and machine learning.
Note that insoft.es is a portfolio site, not a shop: no pricing, no trial, no sign-up, no demo, no documentation, and no published diagnostic performance.
What it does
- Analyze a color fundus photograph of the optic nerve head fully automatically
- Identify the optic disc margin using deep learning
- Estimate the topographic distribution of hemoglobin in the optic nerve
- Compute optic disc cupping from a two-dimensional image
- Return a result within seconds, remotely, over the internet
- Support glaucoma screening and diagnosis from images received from anywhere in the world
- Under development: relate perfusion information to functional perimetry data for a joint assessment
When to use Laguna ONhE / When not to
A quick filter to help you decide if Laguna ONhE is the right fit.
When to use Laguna ONhE
- Ophthalmologists looking for a quantitative glaucoma indicator from a routine color fundus photograph
- Optometrists and remote screening services, since the method receives images from anywhere in the world
- Clinics and health centres with no OCT, as the analysis needs only a color photograph of the eye fundus
- Clinical research teams in ophthalmology that want reproducible quantitative indices of optic nerve hemoglobin and cupping
- Publicly funded ocular imaging R&D projects, the context in which the developer presents the tool
When not to use Laguna ONhE
- Buyers expecting to purchase or trial the tool directly from the developer: insoft.es has no pricing, no trial, no sign-up and no demo
- Teams that need installable software or an API: there is no documentation, no endpoint and no application subdomain
- Organizations that require a documented contractual framework, since the site publishes no terms, no privacy policy and no legal notice
- Use cases outside ophthalmology: the site describes the method only on the optic nerve head
- Users expecting structured product support: the developer is a two-person company reachable through a single generic mailbox
How to use Laguna ONhE
A typical end-to-end flow, from setup to results.
- Read the method description on the developer's About page, the only page that documents what Laguna ONhE does
- Accept that no sign-up, account creation or purchase path exists on insoft.es
- Reach the tool through the third party named by the developer: the telemedicine platform of Retinalyze System A/S, where it is offered as RetinaLyze Glaucoma
- Alternatively, contact INSOFT at admin@insoft.es or by telephone on 922-288490 to ask about access
- Capture a color fundus photograph of the optic nerve head with an ordinary retinal camera; no OCT is required
- Send the image over the internet, the method accepting fundus images from anywhere in the world
- Let the algorithm run on its own: it identifies the optic disc margin, estimates the hemoglobin distribution and computes cupping
- Retrieve the result, which the developer says is returned in a few seconds
- Expect no technical prerequisite, installation guide or configuration step from the developer, because none is documented anywhere on the site
Pros & Cons
Pros
- Needs only a color fundus photograph, hardware that is widespread and far cheaper than an OCT
- Fully automatic and fast, the developer stating a result in a few seconds
- Works remotely over the internet, which fits telemedicine screening
- Backed by a long scientific and industrial record: earlier methods from the same team, TOP, Pulsar, Spark, TNT and PATH, became visual field standards on Octopus and OCULUS instruments
- Established intellectual property, with three national patents cited by name in the United States, Germany and Japan
- CE mark declared by the developer
- Development still active and publicly funded through ERDF 2021-2027 and CDTI
Cons
- No direct access: the tool is not sold by INSOFT but commercialized by a third party, Retinalyze System A/S
- No price, no plan and no free trial published anywhere on the developer's site
- No legal page at all: no terms of service, no privacy policy, no legal notice, no cookie page
- No GDPR information whatsoever, although the data processed are health data
- No diagnostic performance published: no sensitivity, no specificity, no cohort size, no study
- No technical documentation, no API, no mobile app and no social channel
- A very thin site: three real pages plus nine untouched Wix template pages left public in the sitemap, and a footer frozen on 2022
Pricing & Plans
No price is published. The developer's site has no pricing page, the /pricing and /precios paths returning genuine 404 responses, the complete Wix sitemap listing twelve URLs none of which is commercial, and no amount appearing in the text or in the archived HTML of any page. No free plan, no free trial and no offer of any kind is mentioned. The only economic statement published concerns the developer rather than the buyer: INSOFT states that it has been receiving, and still receives, royalties per instrument or program sold, from the companies it has worked for. Because Laguna ONhE is distributed on the telemedicine platform of Retinalyze System A/S, any figure a prospective user may find would be that third party's price for its own offering rather than the price of Laguna ONhE, and it is therefore deliberately not reproduced here. A quotation has to be requested from Retinalyze System A/S, or from INSOFT at admin@insoft.es.
Data, GDPR & hosting
A consolidated view of how Laguna ONhE handles your data.
GDPR overview
INSOFT is established in the European Union, as a Spanish company registered in Santa Cruz de Tenerife under tax number B38252409, so the GDPR applies to it. Yet the site publishes no GDPR information whatsoever: no privacy policy, no legal basis, no statement of data subject rights, no data protection officer and no processing information. An Article 27 representative is not relevant here, the developer already being established in the EU. The site neither claims GDPR compliance nor denies it. The silence deserves attention, because the data at stake are fundus images used for a diagnostic purpose, which fall under the special categories of Article 9. Any documented data protection framework would have to come from Retinalyze System A/S, the platform through which the method is distributed.
Who owns the data?
INSOFT publishes no terms of service, no privacy policy, no legal notice and no cookie page. The complete sitemap lists twelve URLs and none of them is a legal page, and the usual legal paths return genuine 404 responses. Ownership of the fundus images submitted for analysis and of the results produced is therefore defined nowhere by the developer, and no clause states what INSOFT may do with them, or with whom they may be shared. The only ownership the site does document is intellectual property over the method itself, protected by patents US20140340636A1, DE112012004879T5 and JP5960835B2. Processing runs on the platform of Retinalyze System A/S, whose conditions are not reproduced on insoft.es.
Reuse rights
The site makes no statement at all about what happens to user data, so nothing indicates whether an end user may reuse the submitted images or the results without asking permission, nor what they would be allowed to do with them. What the developer does document runs in the opposite direction: the models were trained upstream on large quantities of images (Big Data) within a publicly funded research project. Whether images sent by users feed any further training is never addressed, and no training opt-out is described or declared unavailable. Any usable reuse rule would have to come from Retinalyze System A/S, the third party that commercializes the method, since insoft.es sets out none.
Data retention & training
Hosting summary
Two different things have to be kept apart here. The showcase site insoft.es is a Wix site: its apex domain resolves to 23.236.62.147, an address belonging to Google LLC and located in Council Bluffs, Iowa, in the United States. That is where the web pages are served from, and nothing more. Where the fundus images submitted to Laguna ONhE are processed and stored is declared nowhere. The site publishes no privacy policy, no terms and no legal notice, and names no hosting country, region, data centre or subprocessor for the analysis itself. Since the method is commercialized on the telemedicine platform of the Danish company Retinalyze System A/S, processing runs through that third party, whose own hosting arrangements are not documented on insoft.es. The result is a genuine blind spot: the only hosting fact that can be established concerns a marketing website in the United States, while the health data that actually matter travel through a channel of undisclosed jurisdiction. Anyone under a clinical or regulatory obligation should obtain that information in writing from Retinalyze System A/S before use.
Things to keep in mind
Risks and trade-offs to weigh before adopting Laguna ONhE.
- Access does not run through the developer. The site states that Laguna ONhE is commercialized on the telemedicine platform of Retinalyze System A/S in Denmark, so every price, contract and service commitment belongs to that third party and not to INSOFT. Read the third party's terms before assuming anything about the tool.
- There is no legal page at all: no terms of service, no privacy policy, no legal notice and no cookie page, confirmed both by probing the usual paths and by reading the complete sitemap. For a workflow handling health data that is a serious gap, and it leaves the user with no documented rule on data ownership, retention or deletion.
- The CE mark is declared, not evidenced. The site states that the method holds one, but publishes no certificate number, no notified body and no device class. Verify it directly before relying on that claim in any clinical or procurement decision.
- No diagnostic performance is published: no sensitivity, no specificity, no cohort size, no study reference. Nothing on the site supports a judgment on how well the algorithm detects glaucoma, and none should be inferred from the patents or the CE claim. An automated index with no published accuracy must never be allowed to displace clinical judgment or a full examination.
- Do not mistake the developer's portfolio for the product. insoft.es presents six methods, and five of them, TOP, Pulsar, Spark, TNT and PATH, are not AI and are embedded in OCULUS and Haag-Streit instruments. Only Laguna ONhE is the AI tool described on this page.
- Website hosting is not image processing. The showcase site runs on Wix behind Google infrastructure in the United States, but where the fundus images themselves are processed and stored is declared nowhere. The first must never be read as an answer to the second.
- Continuity is a real question. The developer is a two-person company built around a single researcher, the footer is frozen on 2022, nine unedited Wix template pages remain publicly indexed through the sitemap, and the funded R&D project ended on 30 April 2026 with no published outcome.
Setup & Integrations
Technical difficulty
No installation or configuration procedure is published, and the site states no technical prerequisite of any kind. In use, the method is described as fully automatic once an image has been sent: the analysis runs over the internet and returns a result in seconds, which points to a very low technical barrier for the clinician. The real difficulty is commercial rather than technical. insoft.es offers no sign-up path, so obtaining access means going through the third-party distributor, Retinalyze System A/S, or emailing the developer at admin@insoft.es and waiting for a reply.
Deployment
Integrations
Behind Laguna ONhE
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What does Laguna ONhE do?
What technology does it rely on?
What equipment do you need to use it?
How long does an analysis take?
Who develops Laguna ONhE?
How do you get access to the tool?
How much does Laguna ONhE cost?
Is Laguna ONhE certified as a medical device?
Is there an API or a mobile app?
What does the site say about personal data and the GDPR?
Should you pick Laguna ONhE?
Laguna ONhE is narrow, and it is serious. It rests on more than thirty years of academic and industrial research: INSOFT was founded in 1990 by a professor of ophthalmology, and the team's earlier visual field methods, TOP, Pulsar, Spark, TNT and PATH, ended up embedded in Haag-Streit and OCULUS instruments. The algorithm is covered by patents in the United States, Germany and Japan, the developer declares a CE mark, and development was still publicly funded until 30 April 2026 under project IDI-20240516.
What you will not find is a product. insoft.es is the portfolio of a two-person R&D company, not a software store: no price, no free plan, no trial, no sign-up, no demo, no documentation, and no legal page of any kind, not even a privacy policy, although the data at stake are fundus images used for a diagnostic purpose. Access does not run through INSOFT either: the site states that Laguna ONhE is commercialized on the telemedicine platform of the Danish company Retinalyze System A/S, so pricing, contract and service commitments belong to that third party.
Two claims call for caution. The CE mark is asserted with no certificate number, no notified body and no device class, so read it as a declaration rather than a verified certification. And no diagnostic performance is published: no sensitivity, no specificity, no cohort, no study. Nothing on the site supports a judgment on accuracy.
The realistic audience is clinical ophthalmology and research, not a self-serve software buyer. If the idea appeals, a glaucoma indicator from a simple color fundus photograph with no OCT, the practical next step is the RetinaLyze platform, or an email to INSOFT.
- Choosing a selection results in a full page refresh.
- Opens in a new window.